Vyndaqel romps away in US, spurring earnings hike from PfizerPfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its Share XVyndaqel romps away in US, spurring earnings hike from Pfizerhttps://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/
Alnylam gears up for first RNAi therapeutic filing in 2017US biotech Alnylam says it could file its first product in 2017, a rare disease drug using what Share XAlnylam gears up for first RNAi therapeutic filing in 2017https://pharmaphorum.com/news/alnylam-gears-up-for-first-rnai-therapeutic-filing-in-2017/
